BioCentury | Feb 17, 2017
Financial News

Dermata completes venture financing

...On Feb. 16, dermatology company Dermata Therapeutics LLC (San Diego, Calif.) raised $5 million in a series A...
...Bank. The remaining $2.5 million is available subject to milestones. Dermata Therapeutics LLC , San Diego, Calif. Alicia Parker Dermata Therapeutics LLC...
BioCentury | Jan 20, 2017
Clinical News

DMT210: Ph II DMT210-003 started

...Dermata has exclusive, worldwide rights to DMT210 from Signum (see BioCentury, April 27, 2015 ). Dermata Therapeutics LLC...
...Patient Severity Assessment of Erythema; safety Status: Phase II started Milestone: Phase II data (2H17) Julian Zhu DMT210 SIG990 Dermata Therapeutics LLC Signum...
BioCentury | Dec 9, 2016
Clinical News

DMT210: Ph II DMT210-02 started

...Dermata has exclusive, worldwide rights to DMT210 from Signum (see BioCentury, April 27, 2015 ). Dermata Therapeutics LLC...
...Global Assessment (IGA) score and safety Status: Phase II started Milestone: Phase II data (1H17) Julian Zhu DMT210 SIG990 Dermata Therapeutics LLC Signum...
BioCentury | Oct 3, 2016
Clinical News

SIG990: Phase I data

...The company has exclusive, worldwide rights to DMT210 from Signum (see BioCentury, April 27, 2015). Dermata Therapeutics LLC...
BioCentury | May 23, 2016
Clinical News

SIG990: Phase I started

...patients. Dermata has exclusive, worldwide rights to DMT210 from Signum (see BioCentury, April 27, 2015). Dermata Therapeutics LLC...
BioCentury | Apr 27, 2015
Company News

Signum Dermalogix, Dermata Therapeutics deal

...details, and Dermata did not respond to inquiries. Signum Dermalogix Inc. , Monmouth Junction, N.J. Dermata Therapeutics LLC...
Items per page:
1 - 6 of 6
BioCentury | Feb 17, 2017
Financial News

Dermata completes venture financing

...On Feb. 16, dermatology company Dermata Therapeutics LLC (San Diego, Calif.) raised $5 million in a series A...
...Bank. The remaining $2.5 million is available subject to milestones. Dermata Therapeutics LLC , San Diego, Calif. Alicia Parker Dermata Therapeutics LLC...
BioCentury | Jan 20, 2017
Clinical News

DMT210: Ph II DMT210-003 started

...Dermata has exclusive, worldwide rights to DMT210 from Signum (see BioCentury, April 27, 2015 ). Dermata Therapeutics LLC...
...Patient Severity Assessment of Erythema; safety Status: Phase II started Milestone: Phase II data (2H17) Julian Zhu DMT210 SIG990 Dermata Therapeutics LLC Signum...
BioCentury | Dec 9, 2016
Clinical News

DMT210: Ph II DMT210-02 started

...Dermata has exclusive, worldwide rights to DMT210 from Signum (see BioCentury, April 27, 2015 ). Dermata Therapeutics LLC...
...Global Assessment (IGA) score and safety Status: Phase II started Milestone: Phase II data (1H17) Julian Zhu DMT210 SIG990 Dermata Therapeutics LLC Signum...
BioCentury | Oct 3, 2016
Clinical News

SIG990: Phase I data

...The company has exclusive, worldwide rights to DMT210 from Signum (see BioCentury, April 27, 2015). Dermata Therapeutics LLC...
BioCentury | May 23, 2016
Clinical News

SIG990: Phase I started

...patients. Dermata has exclusive, worldwide rights to DMT210 from Signum (see BioCentury, April 27, 2015). Dermata Therapeutics LLC...
BioCentury | Apr 27, 2015
Company News

Signum Dermalogix, Dermata Therapeutics deal

...details, and Dermata did not respond to inquiries. Signum Dermalogix Inc. , Monmouth Junction, N.J. Dermata Therapeutics LLC...
Items per page:
1 - 6 of 6